Entrada Therapeutics Income Statement (2020-2026) | TRDA

Income Statement Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026
Revenue & cost
Revenue (Quarter)
25.26M18.17M43.73M41.85M59.12M94.69M19.57M37.40M20.56M1.95M1.61M1.30M0.88M
Operating items
Research & Development (Quarter)
6.83M10.51M12.36M15.72M16.25M18.96M15.69M23.10M26.30M22.19M28.29M28.61M32.03M31.26M33.41M32.07M37.88M38.36M33.96M33.05M
Selling, General & Administrative (Quarter)
3.08M3.85M6.10M6.43M7.33M6.98M9.89M7.94M8.17M7.53M8.65M9.40M9.24M9.97M9.86M10.27M10.92M10.30M9.55M10.12M
Operating Expenses (Quarter)
9.91M14.36M18.46M22.15M23.58M25.94M25.58M31.04M34.47M29.72M36.94M38.01M41.27M41.23M43.27M42.35M48.80M48.66M43.51M43.18M
Operating Income (Quarter)
-9.91M-14.36M-18.46M-22.15M-23.58M-25.94M-25.58M-5.78M-16.30M14.01M4.91M21.11M53.42M-21.66M-5.87M-21.79M-46.85M-47.05M-42.21M-42.30M
EBIT (Quarter)
-9.91M-14.36M-18.46M-22.15M-23.58M-25.94M-25.58M-5.78M-16.30M14.01M4.91M21.11M53.42M-21.66M-5.87M-21.79M-46.85M-47.05M-42.21M-42.30M
Non-operating items
Interest & Investment Income (Quarter)
0.01M-0.07M0.04M0.48M0.40M0.80M-3.74M2.66M4.22M4.05M4.29M4.21M4.37M5.77M5.13M4.44M3.92M3.57M3.14M2.62M
Other Non Operating Income (Quarter)
0.01M-0.07M0.01M0.48M0.40M0.80M0.95M2.66M4.22M4.05M4.29M4.21M4.37M5.77M5.13M4.44M3.92M3.57M3.14M2.62M
Net income details
EBT (Quarter)
-9.90M-34.46M-47.36M-21.67M-23.18M-25.14M-24.63M-3.12M-12.08M18.06M9.20M25.33M57.79M-15.89M-0.74M-17.35M-42.92M-43.48M-39.07M-39.68M
Tax Provisions (Quarter)
3.55M13.85M-17.40M18.70M1.83M2.80M-1.86M-1.87M0.20M0.65M0.10M0.04M
Profit After Tax (Quarter)
-9.90M-18.46M-21.67M-23.18M-25.62M67.93M-6.67M-25.93M0.51M-11.11M-0.44M-0.08M1.30M0.12M-17.35M-0.04M0.22M-143.72M-0.41M
Income from Continuing Operations (Quarter)
-9.90M-34.46M-47.36M-21.67M-23.18M-25.14M-24.63M-6.67M-25.93M35.46M-9.50M23.50M54.99M-14.03M1.13M-17.35M-43.12M-44.13M-39.17M-39.72M
Consolidated Net Income (Quarter)
-9.90M-34.46M-47.36M-21.67M-23.18M-25.14M-24.63M-6.67M-25.93M35.46M-9.50M23.50M54.99M-14.03M1.13M-17.35M-43.12M-44.13M-39.17M-39.72M
Income towards Parent Company (Quarter)
-9.90M-34.46M-47.36M-21.67M-23.18M-25.14M-24.63M-6.67M-25.93M35.46M-9.50M23.50M54.99M-14.03M1.13M-17.35M-43.12M-44.13M-39.17M-39.72M
Net Income towards Common Stockholders (Quarter)
-9.90M-34.46M-47.36M-21.67M-23.18M-25.14M-24.63M-6.67M-25.93M35.46M-9.50M23.50M54.99M-14.03M1.13M-17.35M-43.12M-44.13M-39.17M-39.72M
Additional items
EPS (Basic) (Quarter)
-7.56-23.36-7.56-0.69-0.74-0.80-0.79-0.21-0.781.07-0.290.701.61-0.350.03-0.42-1.04-1.06-0.95-0.95
EPS (Diluted) (Quarter)
-7.56-23.36-7.56-0.69-0.74-0.80-0.79-0.21-0.781.02-0.290.681.55-0.350.03-0.42-1.04-1.06-0.95-0.95
Shares Outstanding (Quarter)
1.31M1.48M6.27M31.25M31.28M31.30M31.29M32.37M33.16M33.28M33.05M33.50M34.18M40.63M37.31M41.07M41.34M41.46M41.37M41.84M
Shares Outstanding (Diluted) (Quarter)
1.31M1.48M6.27M31.25M31.28M31.30M31.29M32.37M33.16M34.78M33.05M34.79M35.51M40.63M39.00M41.07M41.34M41.46M41.37M41.84M
EBITDA (Quarter)
-9.91M-14.36M-18.46M-22.15M-23.58M-25.94M-25.58M-5.78M-16.30M14.01M4.91M21.11M53.42M-21.66M-5.87M-21.79M-46.85M-47.05M-42.21M-42.30M
Interest Expenses (Quarter)
20.03M28.94M34.10M31.87M29.63M-5.61M5.40M102.40M8.83M-13.16M0.28M0.35M0.01M62.94M0.13M0.11M0.02M0.02M
Tax Rate (Quarter)
-113.70-114.62-96.33203.337.234.8511.70253.04-0.47-1.50-0.26-0.10